NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
23/02/2026
Voltar para busca
Dado oficial do USPTO
PF 72
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
17/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10
Data de depósito
02/02/2018
Data de registro
30/04/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/02/2026
Última transação
17/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
Seoul, KR
Examinador
SEVERSON, JUSTIN
Localização atual
Historical data usage
Descrição da marca
The mark consists of the letters "PF" and the numbers "72" separated by a shaded rectangle, arranged vertically.
Titulares e representantes
Titulares
Tgel Bio Co., Ltd.
Tgel Bio Co., Ltd.
Representantes
John P. McCormick Fish & Richardson P.C.
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; microspheres used as vehicles to deliver drugs in the nature of pharmaceutical preparations; pharmaceutical preparations and substances for use in drug delivery in cell and tissue; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substancesdrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery formulations in the form of tabletscapsulessolutionssuspensionspellets with tamper resistant properties which facilitate or allow the delivery of a wide range of pharmaceuticals; peptides for drug deliverydrug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; carriers for drug deliverydrug delivery agent in the form of nanoparticle for transferring siRNA in the cell; drug delivery agents that facilitate the delivery of a wide range of pharmaceuticals; drug delivery agents in the form of dissolvable films and coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals ; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements; drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals
Classe 10
Drug delivery apparatus for medical purposesusing microspheres for embolization; electromagnetic drug delivery apparatus for medical use; drug infusion pump; drug delivery devices; implantable drug delivery pump for use as drug delivery device sold empty; implantable medication infuser for use as drug delivery device sold empty; drug delivery platforms; implantable subcutaneous drug delivery devices sold empty; anaesthetic delivery apparatus; medical drug syringes; medical apparatus for introducing pharmaceutical preparations into the human body; medical apparatus for facilitating the inhalation of pharmaceutical preparations; surgical instruments and apparatus; medical products being medical syringes; implants consisting of artificial materials; orthopedic articlesorthopedic walkers and orthopedic supports
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
23/02/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
23/02/2026
ES71
TEAS SECTION 71 RECEIVED
30/10/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
30/04/2024
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
30/06/2020
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
16/06/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/03/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/03/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/02/2020
FIMP
FINAL DISPOSITION PROCESSED
18/02/2020
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
18/02/2020
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
16/10/2019
PLGL
ASSIGNED TO PARALEGAL
16/10/2019
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
25/09/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/07/2019
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
13/05/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
30/04/2019
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
12/04/2019
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
12/04/2019
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
04/04/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/02/2019
PUBO
PUBLISHED FOR OPPOSITION
12/02/2019
GPNX
NOTIFICATION PROCESSED BY IB
08/02/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/01/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
23/01/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/01/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/12/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/12/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/12/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/12/2018
RFNT
REFUSAL PROCESSED BY IB
07/07/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/06/2018
RFRR
REFUSAL PROCESSED BY MPU
21/06/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/06/2018
CNRT
NON-FINAL ACTION WRITTEN
12/06/2018
MAFR
APPLICATION FILING RECEIPT MAILED
12/06/2018
DOCK
ASSIGNED TO EXAMINER
08/06/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/06/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/06/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PF 72 ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.